story of the week
Efficacy and Safety of T-DM1 + Capecitabine vs T-DM1 Alone in Previously Treated ERBB2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
JAMA Oncol 2020 Jun 25;[EPub Ahead of Print], J Cortés, V Diéras, S Lorenzen, F Montemurro, J Riera-Knorrenschild, P Thuss-Patience, G Allegrini, M De Laurentiis, C Lohrisch, E Oravcová, JM Perez-Garcia, F Ricci, D Sakaeva, R Serpanchy, J Šufliarský, M Vidal, N Irahara, C Wohlfarth, M Aout, K GelmonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.